Pfizer Is “Too Big to Nail” and Created Shell Companies to Take the Fall for Its Crimes

Youtube
image_pdf
  • Save
image_print
  • Save
In 2009, Pfizer pushed its drug Bextra to be used off-label for unapproved applications, was prosecuted for illegal marketing of a drug, and paid a $2.3 billion settlement. Under the law, a company convicted of fraud would automatically be kicked out of Medicare and Medicaid and Pfizer would no longer be able to bill any federal health programs for any of its products, which would collapse the company. But Pfizer was “too big to nail.” This video shows how Pfizer cut a deal with federal authorities and created a shell company to take the rap with a criminal plea that allowed Pfizer to continue doing business with Medicare and Medicaid.

Imagine being charged with a crime, but an imaginary friend takes the rap for you.

That is essentially what happened when Pfizer, the world’s largest pharmaceutical company, was caught illegally marketing Bextra, a painkiller that was taken off the market in 2005 because of safety concerns.

When the criminal case was announced last fall, federal officials touted their prosecution as a model for tough, effective enforcement. “It sends a clear message” to the pharmaceutical industry, said Kevin Perkins, assistant director of the FBI’s Criminal Investigative Division.

But beyond the fanfare, a CNN Special Investigation found another story, one that officials downplayed when they declared victory. It’s a story about the power major pharmaceutical companies have even when they break the laws intended to protect patients.

Big plans for Bextra

The story begins in 2001, when Bextra was about to hit the market. The drug was part of a revolutionary class of painkillers known as Cox-2 inhibitors that were supposed to be safer than generic drugs, but at 20 times the price of ibuprofen.

Pfizer and its marketing partner, Pharmacia, planned to sell Bextra as a treatment for acute pain, the kind you have after surgery.

But in November 2001, the U.S. Food and Drug Administration said Bextra was not safe for patients at high risk of heart attacks and strokes.

The FDA approved Bextra only for arthritis and menstrual cramps. It rejected the drug in higher doses for acute, surgical pain.

Promoting drugs for unapproved uses can put patients at risk by circumventing the FDA’s judgment over which products are safe and effective. For that reason, “off-label” promotion is against the law.

If we prosecute Pfizer … a lot of the people who work for the company who haven’t engaged in criminal activity would get hurt.
–Mike Loucks, federal prosecutor

But with billions of dollars of profits at stake, marketing and sales managers across the country nonetheless targeted anesthesiologists, foot surgeons, orthopedic surgeons and oral surgeons. “Anyone that use[d] a scalpel for a living,” one district manager advised in a document prosecutors would later cite.

A manager in Florida e-mailed his sales reps a scripted sales pitch that claimed — falsely — that the FDA had given Bextra “a clean bill of health” all the way up to a 40 mg dose, which is twice what the FDA actually said was safe.

Doctors as pitchmen

Internal company documents show that Pfizer and Pharmacia (which Pfizer later bought) used a multimillion-dollar medical education budget to pay hundreds of doctors as speakers and consultants to tout Bextra.

Pfizer said in court that “the company’s intent was pure”: to foster a legal exchange of scientific information among doctors.

But an internal marketing plan called for training physicians “to serve as public relations spokespeople.”

According to Lewis Morris, chief counsel to the inspector general at the U.S. Department of Health and Human Services, “They pushed the envelope so far past any reasonable interpretation of the law that it’s simply outrageous.”

Pfizer’s chief compliance officer, Doug Lanker, said that “in a large sales force, successful sales techniques spread quickly,” but that top Pfizer executives were not aware of the “significant mis-promotion issue with Bextra” until federal prosecutors began to show them the evidence.

By April 2005, when Bextra was taken off the market, more than half of its $1.7 billion in profits had come from prescriptions written for uses the FDA had rejected.

Too big to nail

But when it came to prosecuting Pfizer for its fraudulent marketing, the pharmaceutical giant had a trump card: Just as the giant banks on Wall Street were deemed too big to fail, Pfizer was considered too big to nail.

Why? Because any company convicted of a major health care fraud is automatically excluded from Medicare and Medicaid. Convicting Pfizer on Bextra would prevent the company from billing federal health programs for any of its products. It would be a corporate death sentence.

Prosecutors said that excluding Pfizer would most likely lead to Pfizer’s collapse, with collateral consequences: disrupting the flow of Pfizer products to Medicare and Medicaid recipients, causing the loss of jobs including those of Pfizer employees who were not involved in the fraud, and causing significant losses for Pfizer shareholders.

“We have to ask whether by excluding the company [from Medicare and Medicaid], are we harming our patients,” said Lewis Morris of the Department of Health and Human Services.

So Pfizer and the feds cut a deal. Instead of charging Pfizer with a crime, prosecutors would charge a Pfizer subsidiary, Pharmacia & Upjohn Co. Inc.

The CNN Special Investigation found that the subsidiary is nothing more than a shell company whose only function is to plead guilty.

Read full article here…

Visit our Classified ads.

Check out our Classified ads at the bottom of this page.

Recent stories & commentary

Classifieds

For classified advertising rates and terms, click here. The appearance of ads on this site does not signify endorsement by the publisher. We do not attempt to verify the accuracy of statements made therein or vouch for the integrity of advertisers. However, we will investigate complaints from readers and remove any message we find to be misleading or that promotes anything fraudulent, illegal, or unethical.

Subscribe
Notify of
guest
4 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
terry shead
terry shead
4 months ago

This is how these criminal cartels get away with causing F murder, it should be stopped, all this crap about to big to fail the same has the cartel criminal banks is garbage? Wake up America!

Ragnar D.
Ragnar D.
4 months ago

It is foolish to believe that the drug companies have any meaningful accountability in the federal FDA system. The biggest offender (Pfizer) got to keep doing business after the Bextra scandal and then got to produce and aggressively market its poison COVID death shot which has already killed and maimed far more people than Bextra. I wouldn’t worry too much about Pfizer’s future because even if it does get prosecuted, it will be the BioN-Tech company that can take the blame this time. See how that works?

Cal
Cal
4 months ago

“Pfizer cut a deal with federal authorities …” Show me where that is lawful in writing. Those who serve within our governments have WRITTEN DELEGATED powers that are supposed to come directly from the US people. No one else except for the legislators can create any law that is binding on the American people. Not their lackeys, not anyone else who works for them, etc. Holding those who were delegated those powers accountable, including those who misused those written delegated powers as if they had the lawful authority to do so – they do NOT. Our ELECTED legislative branch must… Read more »

trackback
Red Pill Expo Hears of Promising Litigation Against Covid Tyranny – The Truth Hound
3 months ago

[…] However, companies like Pfizer have a Houdiniesque skill of slipping out of the noose. According to a 15 July 2022 report¬†circulated online by Need to¬†Know News (NKN, a production of Red Pill Expo founder G. Edward Griffin), that landmark ruling against¬†Pfizer thirteen years ago failed to serve¬†justice, contrary to the hype. NKN¬†noted: […]